MARKET

OCX

OCX

Oncocyte Corporation
NASDAQ
0.4601
-0.0043
-0.93%
Closed 16:02 12/08 EST
OPEN
0.4600
PREV CLOSE
0.4644
HIGH
0.4800
LOW
0.4140
VOLUME
359.79K
TURNOVER
--
52 WEEK HIGH
2.680
52 WEEK LOW
0.3545
MARKET CAP
54.59M
P/E (TTM)
-0.7022
1D
5D
1M
3M
1Y
5Y
Analyst Ratings for OncoCyte
Benzinga · 12/01 20:01
Expert Ratings for OncoCyte
Benzinga · 12/01 18:03
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Benzinga · 12/01 15:01
Lake Street Downgrades OncoCyte to Hold, Lowers Price Target to $0.5
Benzinga · 12/01 14:13
--Lake Street Downgrades Oncocyte to Hold From Buy, Cuts Price Target to $0.50 From $3
--Lake Street Downgrades Oncocyte to Hold From Buy, Cuts Price Target to $0.50 From $3
MT Newswires · 12/01 10:38
OncoCyte's Chief Executive Ronnie Andrews Steps Down
OncoCyte's Chief Executive Ronnie Andrews Steps Down
MT Newswires · 12/01 03:30
BRIEF-Oncocyte Announces The Appointment Of Louis E. Silverman As A Member Of Its Board Of Directors
Reuters · 11/30 23:07
BRIEF-Oncocyte CEO Ronnie Andrews To Step down
Reuters · 11/30 23:04
More
About OCX
OncoCyte Corporation is a molecular diagnostics company. The Company is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

Webull offers kinds of OncoCyte Corp stock information, including NASDAQ:OCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCX stock methods without spending real money on the virtual paper trading platform.